China Pharma Holdings (CPHI) Cost of Revenue (2010 - 2026)
China Pharma Holdings (CPHI) posted Cost of Revenue of $698049.0 for Q1 2026, down 82.59% on a QoQ basis from $4.0 million in Q4 2025, and down 45.14% year-over-year from $1.3 million in Q1 2025.
China Pharma Holdings (CPHI) Cost of Revenue (2010 - 2026) Analysis & Trends
China Pharma Holdings' Cost of Revenue history runs 17 years deep, the most recent figure standing at $698049.0 for Q1 2026.
- Quarterly Cost of Revenue fell 45.14% year-over-year to $698049.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 188.67% YoY) and the FY2025 annual result came in at $4.3 million, up 708.63% from the prior year.
- Cost of Revenue was $698049.0 for Q1 2026 at China Pharma Holdings, down from $4.0 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $4.0 million in Q4 2025 and bottomed at $78041.0 in Q3 2025.
- A 5-year average of $1.0 million and a median of $266451.0 in 2022 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2024 — Cost of Revenue slumped 93.39% — and 2025, when it surged 2196.82%.
- China Pharma Holdings' Cost of Revenue stood at $2.9 million in 2022, then tumbled by 90.98% to $259552.0 in 2023, then slumped by 32.74% to $174579.0 in 2024, then jumped by 2196.82% to $4.0 million in 2025, then tumbled by 82.59% to $698049.0 in 2026.
- Business Quant data shows CPHI's Cost of Revenue at $698049.0 in Q1 2026, $4.0 million in Q4 2025, and $78041.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | China Pharma Holdings | 33.15 Mn | 32.99 Mn | 285,487.00 | 698,049.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 698,049.00 |
| Mar 31, 2026 | 698,049.00 |
| Dec 31, 2025 | 4.01 Mn |
| Dec 31, 2025 | 4.01 Mn |
| Sep 30, 2025 | 78,041.00 |
| Sep 30, 2025 | 78,041.00 |
| Jun 30, 2025 | 101,292.00 |
| Jun 30, 2025 | 101,292.00 |
| Mar 31, 2025 | 1.27 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 174,579.00 |
| Dec 31, 2024 | 174,579.00 |
| Sep 30, 2024 | 134,603.00 |
| Sep 30, 2024 | 134,603.00 |
| Jun 30, 2024 | 111,455.00 |
| Jun 30, 2024 | 111,455.00 |
| Mar 31, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.66 Mn |
| Dec 31, 2023 | 259,552.00 |
| Dec 31, 2023 | 259,552.00 |